[
    {
        "ExclusionCriteria": "(exclusion criteria not marked) Inclusion Criteria:\n\n1. Ability to understand and willingness to sign written informed consent before performance of any study procedures\n2. Age \u2265 18 years\n3. Participants with solid tumors or lymphomas, confirmed by available histopathology records or current biopsy, that are advanced, nonresectable, or recurrent and progressing since last antitumor therapy, and for which no alternative standard therapy exists.\n4. Participants must have a minimum of one injectable and measurable lesion.\n5. Participants with prior Hepatitis B or C are eligible if they have adequate liver function\n6. Participants with human immunodeficiency virus (HIV) are eligible if on established HAART for a minimum of 4 weeks prior to enrollment, have an HIV viral load \\<400 copies/mL, and have CD4+ T-cell (CD4+) counts \u2265 350 cells/uL\n7. Adequate bone marrow function:\n8. Adequate liver function\n\nExclusion Criteria: Patients will be excluded from this study if they meet any of the following criteria (Part 1a and Part 1b).\n\n1. Other malignancy active within the previous 2 years except for basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast that has completed curative therapy.\n2. Major surgery within 4 weeks before the first dose of study drug.\n3. Brain metastases that are untreated or in the posterior fossa or involve the meninges. Participants with stable or previously treated progressing brain metastases (except in the posterior fossa or involving the meninges) may be permitted in a case-by-case basis at the Sponsor's discretion.\n4. Prolongation of corrected QT (QTc) interval to \\>470 millisecond (ms) for males and females when electrolytes balance is normal.\n5. Females who are breastfeeding or pregnant at screening or baseline\n6. Females of childbearing potential that refuse to use a highly effective method of contraception.\n7. Has uncontrolled or poorly controlled hypertension as defined by a sustained BP \\> 9. Has received prior investigational therapy within 5 half-lives of the agent or 4 weeks before the first administration of study drug, whichever is shorter.\n8. Has had any major cardiovascular event within 6 months prior to study drug 10. Has known hypersensitivity to any component in the formulation of ONM-501\n9. Has an active infection requiring systemic treatment\n10. Is participating in another therapeutic clinical trial\n\nAdditional Exclusion Criteria for ONM-501 in Combination with cemiplimab (Part 1b)\n\n1. Has known hypersensitivity to any component in the formulation of cemiplimab\n2. Has any active or recent history of a known or suspected autoimmune disease or recent history of a syndrome that required systemic corticosteroids (\\>10 mg daily prednisone equivalent)\n3. Has a condition requiring systemic treatment with corticosteroids",
        "NCTId": "NCT06022029"
    },
    {
        "ExclusionCriteria": "* Active untreated brain metastases.\n* Patient has any of the following:\n* Uncontrolled intercurrent illness including, but not limited to, poorly controlled hypertension or diabetes, or ongoing active infection requiring systemic therapy.\n* Patients with primary refractory EOC defined as patients who do not respond to their first platinum-containing regimen or who relapse less than 6 months after completion of that first platinum-containing regimen\n* Psychiatric illness that would limit compliance with study requirements.\n* Treatment with any of the following prior to the first dose of NX-1607: CPI (anti-PD-1, PD-L1, cytotoxic T-lymphocyte-associated protein 4, etc) within 3 weeks; autologous or allogeneic stem cell transplant within 100 days; prior systemic cancer therapy within 3 weeks or 5 half-lives (whichever is shorter) (unless otherwise specified) (including hormonal therapy except for hormonal prophylaxis for a prior malignancy); prior radiotherapy within 2 weeks; prior systemic therapy with nitrosoureas, antibody-drug conjugate, or radio-immuno-conjugate therapy within 6 weeks; use of strong or moderate CYP3A4 inducers or inhibitors within 14 days or 7 days, respectively, or 5 half-lives (whichever is longer)\n* History of CAR-T therapy within 30 days prior to the first dose of NX-1607.\n* Toxicities from previous anti-cancer therapies that have not resolved to baseline levels or to Grade 1 or less except for Grade 2 alopecia and Grade 2 peripheral neuropathy or patients receiving endocrine replacement therapy\n* Patients who experienced Grade 3 or higher irAEs with prior immunotherapy.\n* History of uveitis, or an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.\n* Unable to swallow capsules or has malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction likely to interfere with the delivery, absorption, or metabolism of NX-1607.\n* Known allergies, hypersensitivity, or intolerance to components of NX-1607.\n* Pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of NX-1607.\n* Patient is a man who plans to father a child while enrolled in this study or within 3 months after the last dose of NX-1607 and, as applicable, within 6 months after the last dose of paclitaxel.\n* Patient has had major surgery (e.g., requiring general anesthesia) within 4 weeks before the planned first dose of NX-1607, or will not have fully recovered from surgery, or has surgery planned during the time the patient is expected to participate in the study or within 4 weeks after the last dose of NX-1607. Note: Patients with minor planned surgical procedures to be conducted under local anesthesia may participate.\n* Vaccinated with a live vaccine within 28 days (with the exception of the annual inactivated influenza vaccine) or COVID-19 vaccination within 14 days prior to the first dose of NX-1607.\n* Active known second malignancy with the exception of any of the following:\n\n  * Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer.\n  * Adequately treated Stage I cancer from which the patient is currently in remission and has been in remission for \u2265 2 years.\n  * Low-risk prostate cancer with Gleason score \\< 7 and PSA \\< 10 ng/mL.\n  * Any other cancer from which the patient has been disease-free for \u2265 2 years.\n* Infection with human immunodeficiency virus (HIV)-1 or HIV-2. Exception: Patients with well controlled HIV (e.g., CD4 \\> 350/mm3 and undetectable viral load) are eligible.\n* Current active hepatitis, including hepatitis A (hepatitis A virus immunoglobulin M \\[IgM\\] positive), hepatitis B (hepatitis B virus \\[HBV\\] surface antigen positive), or hepatitis C (hepatitis C virus \\[HCV\\] antibody positive, confirmed by HCV RNA). Patients with HCV with undetectable virus after treatment are eligible. Patients with prior exposure to HBV may be entered if quantitative PCR is negative.\n* Use of systemic corticosteroids (\\> 20 mg prednisone or equivalent) within 15 days (except for prophylaxis for radio diagnostic contrast reactions and/or prophylaxis for patients receiving paclitaxel), or other immunosuppressive drugs within 30 days, prior to the first dose of NX-1607.\n* Use of biotin (i.e., Vitamin B7) or supplements containing biotin higher than the daily adequate intake of 30 \u00b5g \\[NIH 2020\\] (Note: Patients who switch from a high dose to a dose of 30 \u00b5g/day or less at least 1 day prior to Screening assessments are eligible for study entry).\n* Receipt of an IP or has been treated with an investigational device within 3 weeks or 5 half-lives (whichever is shorter) prior to the first dose of NX-1607.\n* Any of the following within 6 months prior to the first dose of NX-1607 or ongoing:\n\n  * Myocardial infarction\n  * Unstable angina\n  * Unstable symptomatic ischemic heart disease\n  * New York Heart Association Class III or IV heart failure\n  * Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events)\n  * Any other significant cardiac condition (e.g., pericardial effusion, restrictive cardiomyopathy, severe untreated valvular stenosis, or severe congenital heart disease)\n  * Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating Investigator in consultation with the Medical Monitor.",
        "NCTId": "NCT05107674"
    },
    {
        "ExclusionCriteria": "* History of Grade \u2265 3 toxicity related to prior T-cell agonist or checkpoint inhibitor therapy (eg, anti-cytotoxic T-lymphocyte-associated antigen 4 \\[CTLA-4\\], or anti-PD- 1/programmed death-ligand 1 \\[PD-L1\\] treatment, or any other antibody or drug specifically targeting T-cell co-stimulation or other immune checkpoint pathways) except those that are unlikely to re-occur with standard countermeasures.\n* Current or recent (within 3 months of study intervention administration) gastrointestinal disease or gastrointestinal surgery (eg, intestinal/gastric/colon resection) that could impact the absorption of study intervention.\n* Any significant acute or chronic medical illness which would interfere with study intervention or follow-up in the opinion of the investigator.\n\nOther protocol-defined criteria may apply.",
        "NCTId": "NCT05888831"
    },
    {
        "ExclusionCriteria": "* Other malignancy within 3 years.\n* Active central nervous system (CNS) metastases (treated, stable CNS metastases are allowed).\n* Uncontrolled Grade 3 or greater infection within 2 weeks.\n* Positive for HBV, HCV or human immunodeficiency virus (HIV).\n* History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids within the past 2 years, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.\n* Use of a strong CYP3A inhibitor within 14 days (dose escalation only).\n* Prior therapy with a topoisomerase 1 inhibitor-based antibody drug conjugate.\n\nNote: Other protocol-defined inclusion/exclusion may apply.",
        "NCTId": "NCT05579366"
    },
    {
        "ExclusionCriteria": "1. Patient has cardiac conditions as listed in the protocol.\n2. Patient has blood pressure (BP) \\>140/90 mmHg.\n3. Patient is pregnant or lactating.\n4. Patient has known untreated, active or uncontrolled brain metastases.\n5. Patient with leptomeningeal disease.\n6. Patient has a known additional malignancy that was progressing or required active treatment within 2 years prior to the first dose of study medication.\n7. Patient has a history of bowel obstruction, including sub-occlusive disease, related to the underlying disease or history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess.\n8. Patient has an active infection requiring IV systemic therapy.\n9. Patient has known hypersensitivity to any components of any study drug or any of its excipients that, in the opinion of the investigator, suggests a high risk for a severe hypersensitivity reaction while on treatment.\n10. Patient has a known clinically significant bleeding disorder.\n11. Patient is currently using oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes for which the dose has not been stable for \\>14 days prior to C1D1.\n12. Patient had hemoptysis \\>2.5 mL within 8 weeks prior to C1D1 or serious bleeding from another site within this time frame.\n13. Patient had a major surgical procedure, or significant traumatic injury within 28 days prior to C1D1.\n14. Patient has an uncontrolled seizure disorder or active neurologic disease.\n15. Patient has a cardiac aneurysm.\n16. Patient has a known psychiatric disorder, substance abuse disorder, or geographical travel limitations that in the opinion of the investigator would interfere with patient's ability to cooperate with the requirements of the study.\n17. Patient has a history or current evidence of any condition, therapy, or laboratory abnormality that may confound the results of the study, interfere with the patient's participation for the full duration of the study, or indicates a condition for which study participation is not in the best interest of the patient, in the opinion of the investigator.\n\n    Cohort A1 and Cohort A2 - CRC only:\n18. Patient has known microsatellite instability-high status.\n\n    Cohort A2 - CRC (navicixizumab + irinotecan) only:\n19. Patient is on dialysis.\n20. Patient has received hepatic intra-arterial chemotherapy.\n\n    Cohort B1 - Gastric/GEJ cancer only:\n21. Patient has experienced weight loss \\>10% over 2 months prior to first dose of study treatment.\n22. Patient has definitive pathologically confirmed HER2 positive metastatic gastric or GEJ adenocarcinoma.\n23. Patient has pre-existing Grade \u22652 peripheral neuropathy, according to CTCAE v5.0.\n\n    Cohort C2 - TNBC (navicixizumab + paclitaxel) only\n24. Patient has pre-existing Grade \u22652 peripheral neuropathy, according to CTCAE v5.0.\n\n    Cohort D1 - Ovarian cancer only:\n25. Patient has non-epithelial ovarian carcinoma.\n26. Patient has ovarian tumors with low malignant potential (ie, borderline tumors).",
        "NCTId": "NCT05453825"
    },
    {
        "ExclusionCriteria": "1. Known hypersensitivity to ST316 or any of its excipients.\n2. Corrected interval between Q and T wave on ECG (QTc) \\> 480 msec using Fredericia's formula.\n3. Symptomatic ascites or pleural effusion. A subject who is clinically stable for 4 weeks following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible.\n4. Known active CNS metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are clinically stable for at least 2 weeks prior to study entry and have no evidence of new or enlarging brain metastases. Subjects with treated brain metastases must also follow the steroid exclusion criterion (#9) listed below.\n5. For expansion phase only: presence of any other active malignancy requiring systemic therapy other than the disease under study.\n6. Concurrent anti-cancer therapy.\n7. Known HIV and positive -",
        "NCTId": "NCT05848739"
    },
    {
        "ExclusionCriteria": "* Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 4 months after the final dose of tobemstomig or pembrolizumab, and 6 months after the final dose of nab-paclitaxel\n* Poor venous access\n* History of malignancy within 5 years prior to consent, except for the cancer under investigation in this study and malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate \\>90%), such as adequately treated carcinoma in situ of the cervix, nonmelanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases\n* History of leptomeningeal disease\n* Pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)\n* Hypercalcemia or hypercalcemia that is symptomatic\n* Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis (granulomatosis with polyangiitis), Sj\u00f6gren syndrome, Guillain-Barr\u00e9 syndrome, or multiple sclerosis\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted\n* Active tuberculosis (TB)\n* Significant cardiovascular/cerebrovascular disease within 3 months prior to consent\n* History or presence of an abnormal ECG that is deemed clinically significant\n* History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as structural heart disease (e.g., severe left ventricular systolic dysfunction, left ventricular hypertrophy), coronary heart disease (symptomatic or with ischemia demonstrated by diagnostic testing), clinically significant electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia, hypocalcemia), or family history of sudden unexplained death or long QT syndrome\n* Major surgical procedure within 4 weeks prior to initiation of study treatment\n* Treatment with therapeutic oral or IV antimicrobials (anti-bacterial, anti-fungal, antiviral, anti-parasitic) within 1 week prior to initiation of study treatment\n* Prior allogeneic stem cell or solid organ transplantation\n* Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the participant at high risk from treatment complications\n* Treatment with a live, attenuated vaccine within 28 days prior to initiation of study treatment\n* Treatment with investigational therapy within 28 days prior to initiation of study treatment\n* Prior treatment with CD137 agonists or anti-CTLA therapeutic antibodies or an anti-LAG3 agent\n* Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and IL-2) within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment\n* Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including, but not limited to, prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF agents) within 2 weeks prior to initiation of study treatment\n* History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins\n* Known hypersensitivity to Chinese hamster ovary cell products or to any component of the tobemstomig or pembrolizumab formulation\n* Known allergy or hypersensitivity to any component of the to nab-paclitaxel formulation",
        "NCTId": "NCT05852691"
    },
    {
        "ExclusionCriteria": "(exclusion criteria not marked) Inclusion Criteria:\n\n* Participants must have histologically confirmed estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative breast cancer (TNBC) defined as ER \\< 5%, PR \\< 5%, and HER2 negative (per 2020 American Society of Clinical Oncology \\[ASCO\\] College of American Pathologists \\[CAP\\] guidelines)\n\n  * NOTE: Participants with weakly ER or PR positive disease, defined as ER and/or PR between 1-4% by immunohistochemistry, are eligible if adjuvant endocrine therapy is not recommended/planned by the treating physician\n* Participants must have American Joint Committee on Cancer (AJCC) 8 anatomic tumor clinical stage either\n\n  * T2-T4, N0, M0 or\n  * T1-T3, N1-2, M0\n  * Note: All participants with clinically suspicious nodes must undergo core needle biopsy or fine needle biopsy per standard clinical practice to pathologically confirm nodal status\n* Participants must have breast and axillary imaging with mammogram and/or ultrasound and/or magnetic resonance imaging (MRI) within 49 days prior to randomization\n\n  * Note: Participants with bilateral invasive breast cancer are eligible if both breast cancers are ER-negative, PR-negative, and HER2-negative provided they meet the other eligibility criteria\n* Participants must not have T4/N+, any N3, or inflammatory breast cancer\n* Participants must not have metastatic disease (M1)\n* Participants must not have received prior systemic therapy or radiation therapy with curative intent for the current breast cancer\n* Participants must not have had previous definitive ipsilateral breast surgery for the current breast cancer\n* Participants must not have current or anticipated use of other investigational agents while participating in this study\n* Participants must not have history of allergic reactions attributed to compounds of similar chemical or biologic composition as study agents\n* Participants must not have severe hypersensitivity (\\>= grade 3) to pembrolizumab or any of its excipients\n* Participants must not have received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. CTLA-4, OX-40, CD137)\n* Participants must not be currently participating in or have participated in a study of an investigational agent or used an investigational device within 28 days prior to randomization\n* Participants must be \\>= 18 years old\n* Participants must have Zubrod performance status of 0-2\n* Participants with evidence of peripheral neuropathy must have it at =\\< grade 1, by Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 5.0, within 28 days prior to randomization\n* Participants must have a complete medical history and physical exam within 28 days prior to randomization\n* Hemoglobin \\>= 9.0 g/dL or \\>= 5.6 mol/L (within 28 days prior to randomization)\n\n  * (Criteria must be met without erythropoietin dependency and without packed red blood cell transfusion within last 2 weeks)\n* Leukocytes \\>= 3 x 10\\^3/uL (within 28 days prior to randomization)\n* Absolute neutrophil count \\>= 1.5 x 10\\^3/uL (within 28 days prior to randomization)\n* Platelets \\>= 100 x 10\\^3/uL (within 28 days prior to randomization)\n* Total bilirubin =\\< 1.5 x institutional upper limit of normal (IULN), OR direct bilirubin =\\< IULN for participants with total bilirubin \\> 1.5 x IULN (unless history of Gilbert's disease. Participants with history of Gilbert's disease must have total bilirubin =\\< 5 x institutional IULN) (within 28 days prior to randomization)\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\\< 3 x institutional upper limit of normal (ULN) (within 28 days prior to randomization)\n* Participants must have a serum creatinine =\\< the IULN OR calculated creatinine clearance \\>= 50 mL/min/1.73m\\^2 using the following Cockcroft-Gault Formula. This specimen must have been drawn and processed within 28 days prior to registration\n* Participants must have adequate cardiac function. Participants must have left ventricular ejection fraction \\>= 50% as assessed by either echocardiography (ECHO) or multigated acquisition scan (MUGA) assessed within 28 days prior to registration. Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification and must be class 2B or better\n* Participants with known human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at randomization and have undetectable viral load test on the most recent test results obtained within 6 months prior to randomization\n* Participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load while on suppressive therapy on the most recent test results obtained within 6 months prior to randomization, if indicated\n\n  * Note: No testing for Hepatitis B is required unless mandated by local health authority\n* Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants currently being treated for HCV infection must have undetectable HCV viral load test on the most recent test results obtained within 6 months prior to randomization, if indicated\n\n  * Note: No testing for hepatitis C is required unless mandated by local health authority\n* Participants with history of diabetes must not have uncontrolled diabetes in the opinion of the treating investigator\n* Participants must not have uncontrolled hypertension in the opinion of the treating investigator\n* Participants must not have had a major surgery within 14 days prior to randomization. Participants must have fully recovered from the effects of prior major surgery in the opinion of the treating investigator\n* Participants must not have severe or active infections within 14 days prior to Randomization, including but not limited to hospitalization for infection, bacteremia, or severe pneumonia\n* Participants must not have a diagnosis of immunodeficiency and be receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to randomization\n* Participants must not have active autoimmune disease that has required systemic treatment in 2 years prior to randomization (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment\n* Participants must not have a history of (non-infectious) pneumonitis that required steroids, or has current (non-infectious) pneumonitis\n* Participants must not have received a live vaccine within 30 days prior to randomization. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist \\[registered trademark\\]) are live attenuated vaccines and are not allowed\n* Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the treatment regimen\n* Participants must not be pregnant or nursing. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of \"reproductive potential.\" In addition to routine contraceptive methods, \"effective contraception\" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen\n* Participants must have one (1) physical 4-5-micron single hematoxylin and eosin (H\\&E) slide from the archival pretreatment diagnostic biopsy available for submission\n* Participants must be offered the opportunity to participate in specimen banking. With participant consent, specimens must be collected and submitted via the Southwest Oncology Group (SWOG) Specimen Tracking System\n* Participants who can complete questionnaires in English, Spanish, or French must be offered the opportunity to participate in the Patient-Reported Outcome study\n* NOTE: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system\n\n  * Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines\n  * For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations\n* As part of the registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system",
        "NCTId": "NCT05929768"
    },
    {
        "ExclusionCriteria": "* Evidence of metastatic disease.\n* Has received prior radiotherapy within 2 weeks of start of study intervention.\n* Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.\n* Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.\n* Has a known history of active TB (Bacillus Tuberculosis).\n* Hypersensitivity to pembrolizumab or any of its excipients.\n* Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., \\> Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.\n* Has had prior chemotherapy or targeted small molecule therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., \\> Grade 1 or at baseline) from adverse events due to a previously administered agent. Note: Subjects with \u2264 Grade 2 neuropathy are an exception to this criterion and may qualify for the study.\n* Has a known additional malignancy that progressed or required treatment in the last 5 years. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.\n* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain parenchymal metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis, which is excluded regardless of clinical stability.\n* Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n* Has known history of/active, non-infectious pneumonitis requiring treatment with steroids or has history of/active interstitial lung disease.\n* Has an active infection requiring systemic therapy.\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Is pregnant or breastfeeding, or expecting to conceive within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment. A WOCBP who has a positive urine pregnancy test within 2 weeks prior to start of study treatment (first dose of pembrolizumab). If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. Note: Negative urine or serum pregnancy test is also conducted within 72 hours prior to C1D1 for study procedures but if screening pregnancy test is done within 72 hours of C1D1, it is not required to be repeated..\n* Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).\n* Has a known history of active Hepatitis B (e.g., HBsAg reactive) or known active Hepatitis C (e.g., HCV RNA \\[qualitative\\] is detected).\n* Has received a live vaccine or live-attenuated vaccine within 30 days of planned start of pembrolizumab. Administration of killed vaccines is allowed.\n* Has had an allogenic tissue/solid organ transplant.",
        "NCTId": "NCT05491226"
    },
    {
        "ExclusionCriteria": "* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug\n* Prohibited Treatments and/or Therapies:\n* Chemotherapy, radiation therapy, biological therapy, immunotherapy within 28 days prior to day 1 of protocol therapy\n* Prior immune checkpoint inhibitor therapy in metastatic setting (Note: Prior use of immune checkpoint inhibitor in neoadjuvant or adjuvant setting only permitted if last dose is at least 1 year from start of study intervention)\n* Prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (\u22642 weeks of radiotherapy) to non-CNS disease\n* Any live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Gu\u00e9rin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist\u00ae) are live attenuated vaccines and are not allowed\n* Participants on any dose of warfarin. Use of low molecular weight heparin, antithrombin agents, anti-platelet agents or factor Xa inhibitors is allowed\n* Participants may not be currently participating in or participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention\n* Issues with tolerating oral medication (e.g., inability to swallow pills, malabsorption issues, ongoing nausea or vomiting during screening)\n* Women who are or are planning to become pregnant or breastfeed\n* Known allergy to any of the components within the study agents and/or their excipients\n* No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for at least three years\n* Participants must not have known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study intervention\n* History of (non-infectious) pneumonitis that required steroids or has current pneumonitis\n* Active infection requiring systemic therapy\n* Known history of Human Immunodeficiency Virus (HIV) infection\n* Known history of Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus (defined as HCV RNA \\[qualitative\\] is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority\n* Known history of active TB (Mycobacterium tuberculosis)\n* Intercurrent or historic medical condition that increases subject risk in the opinion of the Investigator. Eligibility may be revisited for intercurrent medical conditions once resolution/recovery is deemed adequate by the investigator (e.g., recovery from major surgery, completion of treatment for severe infection).\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\n* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment\n* Has had an allogenic tissue/solid organ transplant\n* Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) class II, unstable angina, myocardial infarction, or stroke within 6 months of the first dose of study drug, or cardiac arrhythmia requiring medical treatment at screening\n* Subjects having \\> 1+ proteinuria on urine dipstick testing unless a 24-hour urine collection for quantitative assessment indicates that the urine protein is \\< 1 g/24 hours\n* Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed\n* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures",
        "NCTId": "NCT05318469"
    },
    {
        "ExclusionCriteria": "* Medical history and concurrent diseases\n\n  1. Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Note: Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.\n  2. Any underlying medical or psychiatric condition, which in the opinion of the investigator, will make the administration of study drug hazardous or obscure the interpretation of AEs, such as a condition associated with frequent or poorly controlled diarrhea.\n  3. A history of invasive malignancy \u22645 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer, or ovarian cancer.\n  4. Has known active hepatitis B or hepatitis C.\n* Prohibited Treatments and/or Therapies\n\n  1. Chronic use of immunosuppressants and/or systemic corticosteroids (used in the management of cancer or non-cancer-related illnesses). Brief periods of steroid use, for example for the management of chemotherapy-associated toxicities, are allowed. The use of corticosteroids on study is allowed for the treatment of immune related adverse events (irAEs) and other medical conditions including adrenal insufficiency.\n  2. Any non-oncology live vaccine therapy used for prevention of infectious diseases within 3 weeks prior to first dose of ICI.\n  3. Prior investigational agents within 3 weeks prior to ICI administration",
        "NCTId": "NCT03546686"
    },
    {
        "ExclusionCriteria": "Cohort Legend: Cohort 1: On-Treatment Responder (Biopsy), Cohort 2: Pre and On-Treatment (Biopsy), Cohort 3: On-Treatment Responder (Surgery), Cohort 4: Post-Treatment Vitiligo, Cohort 5: Post-Treatment Responder (Frozen)\n\n1. Concurrent disease or condition that would make the patient inappropriate for study participation, or any serious medical or psychiatric disorder that would interfere with safety.\n2. Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.\n3. Research Biopsy Study Cohorts 1,2,4: History of serious or life-threatening allergic reaction to local anesthetics (i.e., lidocaine, xylocaine).\n4. Pregnant women are excluded because there may be an increased risk to both mother and fetus in the setting of moderate sedation, which is required for biopsies of certain anatomic sites (e.g., liver, lung, bone). Also, ionizing radiation from CT-guided biopsies may pose a risk to the unborn fetus.\n5. Research Biopsy Study Cohorts 1,2,4: Active cardiac disease, defined as:\n\ni. Uncontrolled or symptomatic angina within the past 3 months. ii. History of clinically significant arrhythmias (such as ventricular tachycardia, ventricular fibrillation, torsades de pointes). Atrial fibrillation with controlled ventricular response on treatment is not an exclusion.\n\niii. Myocardial infarction \\< 6 months from study entry. iv. Uncontrolled or symptomatic congestive heart failure. f. Any other condition, which in the opinion of the patient's treating oncologist or the physician performing the biopsy procedure, would make participation in this protocol unreasonably hazardous for the patient.",
        "NCTId": "NCT05230186"
    },
    {
        "ExclusionCriteria": "For All Cohorts:\n\n* Subject has preexisting sensory or motor neuropathy Grade \u2265 2.\n* Subject has active central nervous system (CNS) metastases. Subjects with treated CNS metastases are permitted on study if all the following are true:\n\n  * CNS metastases have been clinically stable for \u2265 6 weeks prior to screening\n  * If requiring steroid treatment for CNS metastases, the subject is on a stable dose \u2264 20 mg/day of prednisone or equivalent for \u2265 2 weeks\n  * Baseline imaging scans show no evidence of new or enlarged brain metastasis\n  * Subject does not have leptomeningeal disease\n* Subject has ongoing clinically significant toxicity (Grade 2 or higher with the exception of alopecia) associated with prior treatment (including systemic therapy, radiotherapy or surgery).\n* Subjects with ongoing \u2265 Grade 3 immunotherapy-related hypothyroidism or panhypopituitarism are excluded. Subjects with ongoing immunotherapy-related colitis, uveitis, myocarditis or pneumonitis, or subjects with other immunotherapy-related AEs requiring high doses of steroids (\\> 20 mg/day of prednisone or equivalent), are excluded. Subject with \u2264 Grade 2 immunotherapy-related hypothyroidism or panhypopituitarism may be enrolled when well maintained/controlled on a stable dose of hormone replacement therapy (if indicated).\n* Subject has a history of uncontrolled diabetes mellitus within 3 months before the first dose of study treatment. Uncontrolled diabetes (within 3 months before first dose) is defined as hemoglobin A1c (HbA1c) \u2265 8% or HbA1c between 7 and \\< 8% with associated diabetes symptoms (polyuria or polydipsia) that are not otherwise explained. The lowest HbA1c during the screening period will be used to determine eligibility.\n* Subject has prior treatment with enfortumab vedotin or other monomethyl auristatin E (MMAE) based antibody-drug conjugates (ADCs).\n* Subject has a second malignancy diagnosed within 3 years before first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Subjects with non-melanoma skin cancer, localized prostate cancer treated with curative intent with no evidence of progression, low-risk or very low-risk (per standard guidelines) localized prostate cancer under active surveillance/watchful waiting without intent to treat, or carcinoma in situ of any type (if complete resection was performed) are allowed.\n* Subject is currently receiving systemic antimicrobial treatment for viral, bacterial, or fungal infection at the time of first dose of study treatment. Routine antimicrobial prophylaxis is permitted.\n* Subject has known active hepatitis B (e.g., hepatitis B surface antigen \\[HBsAg\\] reactive) or active hepatitis C (e.g., hepatitis C virus \\[HCV\\] RNA \\[qualitative\\] is detected).\n* Subject has known history of human immunodeficiency virus (HIV) infection (HIV 1 or 2).\n* Subject has documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction or cardiac symptoms (including congestive heart failure) consistent with New York Heart Association Class III-IV within 6 months prior to the first dose of study drug.\n* Subject has major surgery within 4 weeks prior to first dose of study drug.\n* Subject had radiotherapy, chemotherapy, biologics, investigational agents, and/or antitumor treatment with immunotherapy that is not completed 2 weeks prior to first dose of study drug.\n* Subject has known hypersensitivity to enfortumab vedotin or to any excipient contained in the drug formulation of enfortumab vedotin (including histidine, trehalose dihydrate and polysorbate 20) OR subject has known hypersensitivity to biopharmaceutical produced in Chinese hamster ovary cells.\n* Subject has known active keratitis or corneal ulcerations. Subject with superficial punctate keratitis is allowed if the disorder is being adequately treated.\n* Subject has any condition which makes the subject unsuitable for study participation.\n\nCohort 9: 1L HNSCC\n\n* Had PD within 6 months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC.\n* Has had an allogeneic tissue/solid organ transplant. Has severe hypersensitivity (\u2265grade 3) to pembrolizumab and/or any of its excipients.\n* Has a history of (non-infectious) pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease.\n* Has a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.\n* Has a life expectancy of less than 3 months and/or has rapidly progressing disease (e.g. tumor bleeding, uncontrolled tumor pain) in the opinion of the treating investigator.\n* Active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).\n\n  1. Replacement therapy (e.g., thyroxine, insulin, physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.\n  2. Brief (\\<7 days) use of systemic corticosteroids is allowed when use is considered standard of care.\n  3. Subjects with vitiligo, psoriasis, type 1 diabetes mellitus, hypothyroidism, or resolved childhood asthma/atopy will not be excluded.\n  4. Subjects requiring intermittent use of bronchodilators, inhaled steroids, or local steroid injections will not be excluded.\n  5. Subjects with hypothyroidism that is stable with hormone replacement or Sj\u00f6gren's syndrome will not be excluded.\n* Has an active infection requiring systemic therapy.\n* Has received prior therapy with an anti-PD-1 or anti-PD-L1 agent in the recurrent/metastatic setting. If anti-PD-1 or anti-PD-L1 agent was given as part of curative intent therapy, it must be at least 1 year since last dose.\n* Has received a live vaccine within 30 days of planned start of study therapy. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette Gu\u00e9rin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist\u00ae) are live attenuated vaccines and are not allowed.\n* Subject has active tuberculosis",
        "NCTId": "NCT04225117"
    },
    {
        "ExclusionCriteria": "* History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 3 years before randomization and of low potential risk for recurrence.\n* Evidence of distant disease.\n* Clinically significant corneal disease.\n* Has active or uncontrolled hepatitis B or C virus infection.\n* Known HIV infection that is not well controlled.\n* Uncontrolled infection requiring i.v. antibiotics, antivirals or antifungals; suspected infections; or inability to rule out infections.\n* Known to have active tuberculosis infection\n* Resting ECG with clinically significant abnormal findings.\n* Uncontrolled or significant cardiac disease.\n* History of non-infectious ILD/pneumonitis\n* Any prior or concurrent surgery, radiotherapy or systemic anticancer therapy for TNBC or hormone receptor-low/HER2-negative breast cancer\n* For females only: is pregnant (confirmed with positive serum pregnancy test) or breastfeeding, or planning to become pregnant.\n* Female participants should refrain from breastfeeding from enrolment throughout the study and for at least 7 months after last dose of study intervention, or as dictated by local PI for SoC if longer.",
        "NCTId": "NCT06112379"
    },
    {
        "ExclusionCriteria": "* Patients who cannot provide informed consent\n* Patients who cannot see, read, or write\n* Patients who have the cancer and clinical characteristics defined in the inclusion criteria, but who do not speak English or Spanish\n* Patients with none of the listed cancer diagnoses and clinical characteristics\n* Healthcare provider who do not treats cancer patients",
        "NCTId": "NCT06422455"
    },
    {
        "ExclusionCriteria": "1. If the patient received prior therapy with an anti-PD-1 or anti-PD-L1 mAb or with an agent targeting stimulatory or co-inhibitory T-cell receptor and was discontinued from that treatment due to a Grade 3 or higher immune related adverse event.\n2. Received radiotherapy within 2 weeks of treatment.\n3. Received radiotherapy exceeding 30 Gray (Gy) to the lung within 6 months of the first dose of study medication.\n4. Received an allogeneic tissue/solid organ transplant.\n5. Received a live or live-attenuated vaccine within 30 days prior to the first dose of study medication.\n6. Received a VISTA targeting agent.\n7. The patient must have recovered from all AEs due to previous therapies to \u2264Grade 1 or baseline.\n8. The patient has an active autoimmune disease that required systemic treatment in the past.\n9. Presence of an uncontrolled endocrine disorder.\n10. Presence of clinically significant cardiovascular disease.\n11. History of (non-infectious) pneumonitis or interstitial pulmonary disease that required steroids or has current pneumonitis or interstitial pulmonary disease.\n12. Presence of uncontrolled, clinically significant pulmonary disease.\n13. A previous a severe hypersensitivity reaction (\u2265 Grade 3) to pembrolizumab and/or any of its excipients.\n14. A diagnosis of immunodeficiency or is receiving chronic systemic corticosteroids at a dose that exceeds 10 mg daily of prednisone equivalent or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug. Inhaled or topical steroids are permitted in the absence of active autoimmune disease.\n15. An uncontrolled intercurrent illness that would limit compliance with the study.\n16. A positive status for human immunodeficiency virus (HIV).\n17. A known history of Hepatitis B (defined as HBsAg reactive) or known active Hepatitis C viral (defined as HCV RNA detected) infection.\n18. Oxygen-dependence.\n19. A medical condition which, in the opinion of the Investigator, places the patient at an unacceptably high risk for toxicity.\n20. A positive COVID test within one week of study treatment if not fully vaccinated.\n21. Another active malignancy that is progressing or has required active treatment within the past 3 years.\n22. Known active central nervous system metastases and/or carcinomatous meningitis.",
        "NCTId": "NCT05082610"
    },
    {
        "ExclusionCriteria": "* Prior treatment with any agent targeting ROR1 or prior treatment with a CD3 T-cell engaging therapy.\n* Prior treatment with chimeric antigen receptor (CAR) cell therapy within 90 days prior to first dose of NM32-2668.\n* Systemic anti-neoplastic therapy within five half-lives or 21 days, whichever is shorter, prior to first dose of NM32-2668.\n* Wide-field radiotherapy (\\> 30% of marrow-bearing bones) within 28 days, or focal radiation for analgesic purpose or for lytic lesions at risk of fracture within 14 days prior to first dose of NM32-2668, or no recovery from side effects of such prior interventions.",
        "NCTId": "NCT06299163"
    },
    {
        "ExclusionCriteria": "* Subjects currently receiving other anticancer therapies\n* Any prior treatment with an investigational agent targeting CD28\n* History of a life-threatening adverse event related to prior immunotherapy\n* Known active central nervous system involvement by malignant disease. Subjects with previously treated brain metastases may participate provided they are radiologically and clinically stable",
        "NCTId": "NCT05585034"
    },
    {
        "ExclusionCriteria": "* A. Females or males of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 24 weeks after the last dose of study drug.\n* B. Females who are pregnant or breastfeeding.\n* C. History of any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician.\n* D. Hepatitis B infection except for prior vaccination. (Phase I and Phase II only).\n* E. Known history of tuberculosis injection. (Phase I and Phase II only).\n* F. A history of diverticulitis. (Phase I and Phase II only).\n* G. Use of live vaccines within 30 days prior to study treatment due to the risk of infection. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella (MMR), varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Gu\u00e9rin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g. FluMist) are live attenuated vaccines and are not allowed. (Phase I and Phase II only)\n* H. History of other malignancy that in the primary oncologist's estimation has at the time of study participation a higher risk of recurrence or death than the study-related cancer.\n* I. Prisoners or subjects who are involuntarily incarcerated.\n* J. Subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.\n* K. Subjects demonstrating an inability to comply with the study and/or follow-up procedures.",
        "NCTId": "NCT04333706"
    },
    {
        "ExclusionCriteria": "1. Stage IV (metastatic) TNBC.\n2. History of prior invasive breast cancer, or evidence of recurrent disease following preoperative therapy and surgery.\n3. Severe or uncontrolled medical conditions including systemic diseases, history of allogeneic organ transplant and active bleeding diseases, ongoing or active infection, serious chronic gastrointestinal conditions associated with diarrhea chronic diverticulitis or previous complicated diverticulitis.\n4. History of another primary malignancy except for adequately resected basal cell carcinoma of the skin or squamous cell carcinoma of the skin, in situ disease (including ductal carcinoma in situ) that has undergone potentially curative therapy, or other solid malignancy treated with curative intent with no known active disease within 5 years before randomisation and of low potential risk for recurrence.\n5. Persistent toxicities caused by previous anticancer therapy, excluding alopecia, not yet improved to Grade \u2264 1 or baseline. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention may be included (eg, hearing loss).\n6. Active or prior documented autoimmune or inflammatory disorders.\n7. Clinically significant corneal disease.\n8. Active or uncontrolled hepatitis B or C virus infection.\n9. Known HIV infection that is not well controlled\n10. Active tuberculosis infection.\n11. Mean resting corrected QTcF \\> 470 ms regardless of gender, obtained from triplicate 12-lead ECGs performed at screening.\n12. Uncontrolled or significant cardiac disease.\n13. History of non-infectious ILD/pneumonitis including radiation, pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.\n14. Has severe pulmonary function compromise.\n15. Any known active liver disease.\n16. Grade \u2265 2 peripheral neuropathy of any aetiology.\n17. Prior exposure to a PD-1/PD-L1 inhibitor other than pembrolizumab.\n18. Current or prior use of immunosuppressive medication within 14 days prior to randomisation.\n19. Participants with a known severe hypersensitivity to Dato-DXd or any of the excipients of these products including but not limited to polysorbate 80 or other monoclonal antibodies.\n20. Participants with a known severe hypersensitivity to PD-1/PD-L1 inhibitors.\n21. Participation in another clinical study with a study intervention or investigational medicinal device administered in the last 4 weeks prior to randomisation, randomisation into a prior Dato-DXd, T-DXd, or durvalumab study regardless of treatment assignment.\n22. Currently pregnant (confirmed with positive pregnancy test), breastfeeding or planning to become pregnant.",
        "NCTId": "NCT05629585"
    },
    {
        "ExclusionCriteria": "(exclusion criteria not marked) Key Inclusion Criteria For All Phases and Cohorts:\n\n1. Recovered from toxicity to prior anticancer therapy\n2. Adequate bone marrow and organ function\n3. No known active or symptomatic central nervous system (CNS) disease\n\nCohort-Specific Inclusion Criteria: In addition to the inclusion criteria listed above, the following criteria apply for enrollment into specific cohorts.\n\nPhase 1 (NUV-868 Monotherapy)\n\n1. Patients with advanced solid tumors that have progressed during or after treatment with approved therapies or for which there is no standard effective therapy available\n2. Life expectancy of \\> 3 months\n3. Eastern Cooperative Oncology Group Performance Status \u2264 2\n4. Measurable or non-measurable disease\n\nPhase 1b (NUV-868 in Combination With Enzalutamide or Olaparib)\n\n1. Life expectancy of \\> 3 months\n2. Eastern Cooperative Oncology Group Performance Status \u2264 2\n3. (Select cohorts only) Measurable disease\n4. Patient must be able to read and write sufficiently to document food intake and study drug dosing on the Dosing Diary or must have a caregiver who is willing and able to complete the Dosing Diary with the patient.\n5. One of the following tumor types:\n\n   1. Ovarian: Platinum-resistant OR platinum-refractory high grade serous ovarian, fallopian, or primary peritoneal cancer in the relapsed setting\n   2. Pancreatic: Pancreatic ductal adenocarcinoma (PDAC) with progression on or after treatment with at least one line of systemic chemotherapy in the advanced setting\n   3. Prostate: Histologically confirmed, metastatic adenocarcinoma of the prostate (adenocarcinoma/high grade carcinoma with neuroendocrine features is allowed) with progression on or after treatment with at least one NHT in the metastatic setting\n   4. Breast: Triple-negative breast cancer (TNBC) with progression on or after treatment with at least one line of systemic chemotherapy in the advanced setting\n   5. Other advanced tumors (only Phase 1b dose escalation, NUV-868 + olaparib): the study Medical Monitor must approve enrollment.\n   6. For all tumor types: Patients will be allowed in the study regardless of their BRCA/HRR status.\n\nPhase 2\n\n1. Life expectancy of \\> 6 months\n2. (Select cohorts only): At least one measurable lesion defined by standard criteria\n3. Eastern Cooperative Oncology Group Performance Status \u2264 1\n4. One of the following tumor types:\n\n   1. Ovarian: Platinum-resistant or platinum- refractory high grade serous ovarian, fallopian, or primary peritoneal cancer in the relapsed setting\n   2. Pancreatic: Progression on or after treatment with at least one line of systemic chemotherapy in the advanced setting\n   3. Prostate: Histologically confirmed, metastatic adenocarcinoma of the prostate (adenocarcinoma/high grade carcinoma with neuroendocrine features is allowed) with progression on or after treatment with at least one NHT in the metastatic setting\n   4. Breast: TNBC with progression on or after treatment with at least one line of systemic chemotherapy in the advanced setting\n\nKey Exclusion Criteria For All Phases and Cohorts:\n\n1. Have received chemotherapy, hormonal therapy (except for ongoing luteinizing hormone-releasing hormone \\[LHRH\\] analogs in male patients and premenopausal women), radiation, or biological anticancer therapy within 14 days prior to the first dose of NUV-868.\n2. Received treatment with an investigational agent for any indication within 14 days for non-myelosuppressive agent, or within 21 days or \\< 5 half-lives (whichever is longer) for myelosuppressive agent, prior to the first dose of study treatment.\n3. Requires medications that are known to be strong (or moderate for olaparib) inducers and/or strong (or moderate for olaparib) inhibitors of CYP3A4/5 enzymes.\n4. Female patients who are pregnant of breastfeeding.",
        "NCTId": "NCT05252390"
    },
    {
        "ExclusionCriteria": "* Use of any other investigational agents within 30 days of starting study treatment\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study agent or accompanying supportive medications.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements",
        "NCTId": "NCT01042379"
    },
    {
        "ExclusionCriteria": "* No stage IV (metastatic) breast cancer\n* No history of any prior (ipsi- or contralateral) invasive breast cancer. Prior DCIS is allowed\n* No evidence of recurrent disease following preoperative therapy and surgery\n* No known active liver disease, e.g. due to hepatitis B virus (HBV), hepatitis C virus (HCV), autoimmune hepatic disorders, or sclerosing cholangitis\n* No history of intolerance, including Grade 3 or 4 infusion reaction or hypersensitivity to pembrolizumab or murine proteins or any components of the product\n\n  \\* Note: Prior immune-related adverse events (irAEs) are allowed if they resolved and the patient tolerated subsequent therapy without requiring chronic steroids for the irAE\n* No medical conditions that require chronic systemic steroids (\\>10 mg prednisone daily or equivalent) or any other form of immunosuppressive medications and has required such therapy in the last two years. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic therapy\n* Patients who are unable or unwilling to comply with the requirements of the protocol per investigator assessment are not eligible",
        "NCTId": "NCT05812807"
    },
    {
        "ExclusionCriteria": "* Women who are pregnant or breastfeeding\n* Primary central nervous system (CNS) malignancy\n* Untreated CNS metastases\n* Leptomeningeal metastases\n* Concurrent malignancy requiring treatment or history of prior malignancy active within 2 years prior to the first dose of study treatment\n* Active, known, or suspected autoimmune disease\n* Condition requiring systemic treatment with either corticosteroids within 14 days or other immunosuppressive medications within 30 days of the first dose of study treatment\n* Prior organ or tissue allograft\n* Uncontrolled or significant cardiovascular disease\n* Major surgery within 4 weeks of study drug administration\n* History of or with active interstitial lung disease or pulmonary fibrosis\n\nOther protocol-defined inclusion/exclusion criteria apply",
        "NCTId": "NCT04895709"
    },
    {
        "ExclusionCriteria": "* Has a history of malignancy, other than a tumor type specified in the Inclusion Criteria, except (a) adequately resected non-melanoma skin cancer, (b) curatively treated in situ disease, or (c) other solid tumors curatively treated, with no evidence of disease for \u22653 years.\n* Uncontrolled or significant cardiac disease including myocardial infarction or uncontrolled/unstable angina within 6 months prior to Cycle 1 Day 1.\n* History of congestive heart failure (New York Heart Association classes II-IV) or uncontrolled or significant cardiac arrhythmia, uncontrolled hypertension(resting systolic blood pressure \\>180 mm Hg or diastolic blood pressure \\>110 mm Hg).\n* Has a mean corrected QT interval (QTcF) prolongation to \\>470 ms based on of the screening triplicate 12-lead ECGs.\n* Has a history of non-infectious interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.\n* Has clinically significant corneal disease.\n* Has an uncontrolled infection requiring IV antibiotics, antivirals, or antifungals. Has active human immunodeficiency virus (HIV) infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA load, CD4+ count \\>350, no history of AIDS-defining opportunistic infection within the past 12 months, and stable for at least 4 weeks on the same anti-HIV medications. If an HIV infection meets the above criteria, monitoring of viral RNA load and CD4+ count is recommended. Subjects/participants must be tested for HIV during the Screening Period if acceptable by local regulations or an IRB/IEC.\n* Has an active or uncontrolled hepatitis B and/or hepatitis C infection.\n* Has spinal cord compression or clinically active brain metastases, defined as untreated and symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms. Participants with clinically inactive brain metastases may be included in the study. A minimum of 2 weeks must have elapsed between the end of whole brain radiotherapy and study enrollment. Participants with treated brain metastases that are no longer symptomatic and who require no treatment with steroids may be included in the study if they have recovered from the acute toxic effect of radiotherapy.\n* Is lactating or pregnant as confirmed by pregnancy tests performed within 7 days before enrollment.\n* Has unresolved toxicities from previous anticancer therapy.\n* Has a concomitant medical condition that would increase the risk of toxicity, in the opinion of the Investigator.\n* Has a history of severe hypersensitivity reactions to either the drug substances or inactive ingredients of DS-1062a. Has a history of severe hypersensitivity reaction to other monoclonal antibodies.\n* Has any other medical conditions, including cardiac disease or psychological disorders, and/or substance abuse that would increase the safety risk to the participant or interfere with participation of the participant or evaluation of the clinical study in the opinion of the Investigator.\n* Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder, or any autoimmune, connective tissue or inflammatory disorders with pulmonary involvement, or prior pneumonectomy.\n* Has leptomeningeal carcinomatosis.\n* Has substance abuse or any other medical conditions such as clinically significant cardiac or psychological conditions, that may, in the opinion of the investigator, interfere with the participant's participation in the clinical study or evaluation of the clinical study results.\n* Psychological, social, familial, or geographical factors that would prevent regular follow-up. Adults under guardianship, curatorship, safeguard of justice, or family empowerment measure are not eligible.\n* Otherwise considered inappropriate for the study by the investigator.\n\nAdditional Exclusion Criteria for Sub-study:\n\n* Has had any prior oral mucositis/stomatitis that did not resolve within 3 months of signing the ICFs\n* Requires oral steroid or steroid nasal spray or inhaler for asthma, chronic obstructive pulmonary disease, or any other reason at the time of randomization\n* Requires immunosuppressive drugs at the time of randomization\n* Has oral inflammation or infections, including candidiasis (thrush) at the time of randomization\n* Has a history of severe hypersensitivity reactions or any other contraindication to steroids or other active principles or excipients of the mouthwash",
        "NCTId": "NCT03401385"
    },
    {
        "ExclusionCriteria": "* Patients must not have clinically significant cardiac disease.\n* Patients must not have known non-controlled CNS metastasis.\n* Patients must not have a history of \u2265 Grade 3 allergic reactions to mAb therapy as wellas known or suspected allergy or intolerance to any agent given during this study.\n* Patients must not have had major surgery within 4 weeks before first BA3021 administration.\n* Patients must not have had prior therapy with a conjugated or unconjugated auristatin derivative/vinca-binding site targeting payload.\n* Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.\n* Patients must not be women who are pregnant or breast feeding.",
        "NCTId": "NCT03504488"
    },
    {
        "ExclusionCriteria": "* Radiation therapy, chemotherapy, or non-cytotoxic investigational agent within 2 weeks of day 0 (leukapheresis)\n* Received cyclophosphamide within the past 4 months\n* Evidence of New York Heart Association class III or greater cardiac disease\n* History of myocardial infarction, stroke, ventricular arrhythmia, or symptomatic conduction abnormality within the past 12 months\n* History of congenital QT prolongation\n* Absolute QT interval of \\> 470 msec in the presence of \\> 4.0 mEq/L potassium and \\> 1.8 mg/dL magnesium\n* Brain or leptomeningeal metastases\n* Females who are pregnant or breastfeeding\n* Hypersensitivity or intolerance to cyclophosphamide, fludarabine, or their components\n* Alcoholic liver disease or other hepatic disease with the exception of liver metastases\n* History of gastrointestinal bleeding, ulceration, or perforation\n* Any severe and/or uncontrolled medical conditions or other conditions that could affect participation in the study, such as severely impaired lung function, any active (acute or chronic) or uncontrolled infection/disorders, and non-malignant medical illnesses that are uncontrolled or whose control may be jeopardized by the study treatment\n* Current use of medications that interact with or compromise the immune system such as steroid doses \\> 10 mg/day prednisone or equivalent daily within 2 weeks before leukapheresis\n* History of immunodeficiency disease or autoimmune disease\n* Concurrent use of any complementary or alternative medicines\n* Unwilling or unable to comply with the study protocol\n* Prior major surgery that requires general anesthesia must be completed at least 4 weeks before leukapheresis and surgery that requires local anesthesia (except for study tissue sample collection) must be completed at least 2 weeks before leukapheresis",
        "NCTId": "NCT05989828"
    },
    {
        "ExclusionCriteria": "* Stage IV (metastatic) breast cancer as well as history of any prior (ipsi- or contralateral) invasive breast cancer.\n* Prior treatment with another stimulatory or coinhibitory T-cell receptor agent (eg, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), OX-40, cluster of differentiation 137 (CD137), prior treatment with any HER2-directed agent, prior or concurrent treatment with any endocrine therapy agent.\n* Evidence of recurrent disease following preoperative therapy and surgery.\n* Prior treatment with topoisomerase 1 inhibitors or antibody-drug conjugates (ADCs) containing a topoisomerase inhibitor.\n* Individuals with germline breast cancer gene (BRCA) mutations.\n* Myocardial infarction or unstable angina pectoris within 6 months of enrollment or history of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias or Left ventricular ejection fraction (LVEF) of \\< 50%\n* Active serious infections requiring anti-microbial therapy.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
        "NCTId": "NCT05633654"
    },
    {
        "ExclusionCriteria": "1. Bilateral breast cancer.\n2. Prior malignancies that require ongoing active therapy or are at clinically significant risk of systemic recurrence in the opinion of the investigator.\n3. Suspicion for, or histologically confirmed metastatic disease.\n4. Symptomatic primary tumor.\n5. Primary tumor with potential for skin ulceration or invasion of the chest wall, or with pain that would suggest rapid progression or imminent muscle/skin involvement in the opinion of the enrolling investigator.\n6. Prior therapy with an anti-PD-1, anti-PD-L1, or antiPDL2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX40, CD137). Patients who have received these agents more than 3 years prior for other malignancies may be considered if they are not still at clinically significant risk of systemic recurrence in the opinion of the investigator.\n7. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.\n8. Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.\n9. Active autoimmune disease that has required systemic treatment in excess of prednisone 10mg daily or equivalent in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed.\n10. Received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Gu\u00e9rin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist\u00ae) are live attenuated vaccines and are not allowed.\n\n    Additionally, COVID-19 vaccinations (including boosters) should not be scheduled within 72 hours (before or after) of dosing days for INBRX-106 and pembrolizumab.\n11. Participants with a condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses \\> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.\n12. Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n13. Pregnant or breastfeeding.\n14. History of (non-infectious) pneumonitis that required steroids or has current pneumonitis.\n15. History of allogenic tissue/solid organ transplantation.\n16. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Has a known additional malignancy (other than their current breast cancer diagnosis) that is progressing or has required active systemic treatment within the past 3 years.\n\n    Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma cervical cancer in situ) that have undergone potentially curative therapy are not excluded. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.\n17. History or current evidence of any condition, therapy, or clinically significant laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n18. Active infection requiring systemic therapy with the exception of UTI requiring oral antibiotic therapy and prophylactic anti-viral therapy (e.g. Acyclovir).\n19. Known history of Human Immunodeficiency Virus (HIV) infection.\n20. Known history of Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus (defined as HCV RNA \\[qualitative\\] is detected) infection. Patients with naturally acquired immunity are allowed (i.e. HBsAg(-); HBcAb(+); HBsAb(+/-). Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority.\n21. Any known history of active TB (Bacillus Tuberculosis).",
        "NCTId": "NCT06353997"
    }
]